Serum vitamin D and recurrent benign paroxysmal positional vertigo

OBJECTIVES: The objective of the present study was to examine the effects of serum 25‐hydroxyvitamin D concentrations on patients diagnosed with benign paroxysmal positional vertigo (BPPV) on BPPV recurrence. STUDY DESIGN: Case series. METHODS: A retrospective review of 232 patients diagnosed with BPPV visiting the clinic between June 2014 and June 2015 was performed. All patients underwent a complete otolaryngological, audiologic, and neurologic evaluation. The appropriate particle‐repositioning maneuver was performed depending on the type of BPPV. The patients were divided into the recurrence group and the nonrecurrence group. Age, gender, follow‐up period, type of BPPV, and vitamin D concentrations in the two groups were compared and analyzed through binary logistic regression analyses. RESULTS: The average follow‐up period after treatment was 10.2 months. Forty‐one (17.7%) of 232 patients suffered a recurrence during the follow‐up period. The mean vitamin D concentration of 191 patients who did not suffer any recurrence was 16.63 ng/mL, whereas that of 41 patients who suffered a recurrence was 13.64 ng/mL. This difference in vitamin D concentrations was statistically significant (P < 0.019). The patients' age, gender, follow‐up period, and type of BPPV had no statistically significant impact. CONCLUSION: Vitamin D is assumed to affect BPPV as a recurrence factor independent of age, gender, follow‐up period, and type of BPPV. LEVEL OF EVIDENCE: 4.